Patents by Inventor Ji-hye Choi
Ji-hye Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240145118Abstract: A transparent conductor according to an exemplary embodiment of the present invention includes a transparent substrate, and a transparent conductive pattern formed on the transparent substrate, and the transparent conductor includes a nanostructure on an upper surface of at least one of the transparent substrate and the transparent conductive pattern.Type: ApplicationFiled: March 17, 2021Publication date: May 2, 2024Inventors: Dae-Guen CHOI, Hyuk Jun KANG, Ji Hye LEE, Junhyuk CHOI, Won Seok CHANG, Joo Yun JUNG, Jun-ho JEONG
-
Publication number: 20240124328Abstract: The present invention relates to a method for removing a low-boiling point organic compound and, more specifically, to a method for removing a low-boiling point organic compound, capable of suppressing a formation of a salt when the low-boiling point organic compound is removed from a brine solution produced in a process of preparing an aromatic compound. Since the method for removing a low-boiling point organic compound according to the present invention suppresses salt precipitation when a low-boiling point organic compound in brine is removed, it is easy to maintain process facilities and the low-boiling point organic compound may be easily removed.Type: ApplicationFiled: January 26, 2022Publication date: April 18, 2024Inventors: Ji Hye CHOI, Namjin JANG, Jinho PARK
-
Patent number: 11951130Abstract: The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.Type: GrantFiled: March 1, 2021Date of Patent: April 9, 2024Assignee: Eutilex Co., Ltd.Inventors: Byoung S. Kwon, Young Ho Kim, Kwang Hee Kim, Ji Won Chung, Young Gyoon Chang, Bo Rim Yi, Jung Yun Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Eun Hye Yoo
-
Publication number: 20240092712Abstract: The present invention relates to a method for chlorinating an aromatic compound and, more specifically, to a method for chlorinating an aromatic compound to prevent the phenomenon of decreased responsiveness due to foam generation, and to prevent counterflow of a fluid. By means of the method for chlorinating an aromatic compound according to the present invention, a plurality of column-type reactors are connected in series so that reaction products produced in a former reactor are inserted to a latter reactor, and chlorine gas is inserted in equal measure at the bottom of each reactor. Accordingly, a chlorination reaction occurs in each of the reactors, and hydrogen chloride gas generated in each of the reactors is exhausted from each of the reactors.Type: ApplicationFiled: January 25, 2022Publication date: March 21, 2024Inventors: Namjin JANG, Ji Hye CHOI, Jinho PARK
-
Patent number: 11932618Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: GrantFiled: March 13, 2023Date of Patent: March 19, 2024Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Patent number: 11912674Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.Type: GrantFiled: March 4, 2021Date of Patent: February 27, 2024Assignee: IL DONG PHARMACEUTICAL CO., LTD.Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
-
Publication number: 20240051906Abstract: The present invention relates to a cresol preparation method, wherein DTE, a byproduct produced by the cresol preparation method, is separated and recycled to a reaction step, thereby inhibiting the production of DTE. The cresol preparation method according to the present invention is a process in which a cresol is prepared by a reaction of halo-toluene and a basic aqueous solution, and the method comprises a step of separating DTE, a byproduct of the process, and re-feeding DTE to the reaction step of halo-toluene and the basic aqueous solution.Type: ApplicationFiled: December 24, 2021Publication date: February 15, 2024Inventors: Jinho PARK, Kyuho SONG, Ji Hye CHOI, Namjin JANG
-
Publication number: 20240033654Abstract: The present invention relates to a method for removing HCl in a chlorination reaction, and more particularly, to a method capable of efficiently removing HCl produced during a chlorination reaction of an aromatic compound. The present invention includes, in a chlorination reaction in which a final product with a chlorine-substituted terminal is produced in column reactors connected to each other in series, heating hydrogen chloride produced in the chlorination reaction in a stripping column connected to the reactor positioned at the rearmost end, to remove hydrogen chloride.Type: ApplicationFiled: December 14, 2021Publication date: February 1, 2024Inventors: Jinho PARK, Namjin Jang, Ji Hye CHOI
-
Publication number: 20230212140Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: ApplicationFiled: March 13, 2023Publication date: July 6, 2023Inventors: Hong Chul Yoon, Kyung Mi, myong Jae Lee, Jin Hee Lee, Jeong-Geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Patent number: 11643403Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: GrantFiled: November 13, 2020Date of Patent: May 9, 2023Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-Gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Publication number: 20230013143Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: ApplicationFiled: November 13, 2020Publication date: January 19, 2023Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Publication number: 20230002348Abstract: The present invention provides novel compounds of chemical formula 1, optical isomers of the compounds, or a pharmaceutically acceptable salts of the compounds, or the optical isomers. The compounds, isomers, and salts exhibits excellent activity as GLP-1 receptor agonists. Particularly, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used therapeutic agents for metabolic diseases. In addition, they exhibits excellent pharmacological safety for cardiovascular systems.Type: ApplicationFiled: November 13, 2020Publication date: January 5, 2023Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-Gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Patent number: 11447581Abstract: The invention relates to a method for selective hydrogenation. More specifically, it relates to a method for selective hydrogenation capable of improving selectivity and reaction efficiency in the hydrogenation process of petroleum resin.Type: GrantFiled: December 19, 2018Date of Patent: September 20, 2022Assignee: HANWHA SOLUTIONS CORPORATIONInventors: Sang Ho Seo, Ji Hye Choi, Kee Do Han, Seong Ho Park, Bong Sik Jeon
-
Publication number: 20220194998Abstract: The present invention provides an Oct-3/4 protein variant wherein lysine at position 156; lysine at position 286; or lysines at positions 156 and 286 in the Oct-3/4 protein is (are) substituted with arginine. The Oct-3/4 protein variant according to the present invention can inhibit a protein degradation mechanism through ubiquitination, and shows a higher half-life, compared to the wild-type Oct-3/4, thereby exhibiting high stability.Type: ApplicationFiled: February 6, 2020Publication date: June 23, 2022Applicant: CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Kwang-Hyun BAEK, Ji-Hye CHOI
-
Publication number: 20220144774Abstract: Provided are a novel process for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof, which is an intermediate useful for the preparation of tofacitinib, an intermediate used in the process, i.e., isopropanol solvate of methyl ((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)carbamate dibenzoyl-L-tartrate, an intermediate, having excellent stability, useful for the preparation of tofacitinib, i.e., (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine acetate, and a process for preparing tofacitinib or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 3, 2020Publication date: May 12, 2022Applicant: YUHAN CORPORATIONInventors: Sang-Ho OH, Doo-Byung LEE, Kyoung-Chan KWON, Sang-Won KIM, Hyo-Ick HWANG, Kyeong-Sill LEE, Ik-Su JO, Ji-Hye CHOI, Sung-Hee CHO, Su-Young LEE
-
Publication number: 20220125929Abstract: Disclosed are a pharmaceutical composition for anionic drug delivery, and a preparation method therefor, the pharmaceutical composition for anionic drug delivery containing: an anionic drug as an active ingredient; a cationic compound; an amphiphilic block copolymer; and a polylactate, wherein the anionic drug formed a complex with the cationic lipid, and the complex is encapsulated within a micelle structure formed by the amphiphilic block copolymer and the polylactate.Type: ApplicationFiled: January 10, 2022Publication date: April 28, 2022Applicant: SAMYANG HOLDINGS CORPORATIONInventors: Hye Yeong NAM, Bong-Oh KIM, Min-Hyo SEO, Ji-Yeon SON, Ji-Hye CHOI, Sang Hoon KIM
-
Patent number: 11253598Abstract: Disclosed are a pharmaceutical composition for anionic drug delivery, and a preparation method therefor, the pharmaceutical composition for anionic drug delivery containing: an anionic drug as an active ingredient; a cationic compound; an amphiphilic block copolymer; and a polylactate, wherein the anionic drug formed a complex with the cationic lipid, and the complex is encapsulated within a micelle structure formed by the amphiphilic block copolymer and the polylactate.Type: GrantFiled: September 12, 2016Date of Patent: February 22, 2022Inventors: Hye Yeong Nam, Bong-Oh Kim, Min-Hyo Seo, Ji-Yeon Son, Ji-Hye Choi, Sang Hoon Kim
-
Publication number: 20220009933Abstract: The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient, wherein the tricyclic compound represented by Chemical Formula 1 has an excellent inhibitory activity against IRAK4, and thus can be usefully used for the prevention, treatment, or alleviation of autoimmune diseases or tumors.Type: ApplicationFiled: November 20, 2019Publication date: January 13, 2022Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Heeyeong Cho, Hee-Jong Lim, Woo Kyu Park, Dae Young Jeong, Hyeon Young Kim, Sae-Bom Yoon, Chong Ock Lee, Heung Kyoung Lee, Victor Sukbong HONG, Ji Hye Choi
-
Publication number: 20210188790Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.Type: ApplicationFiled: March 4, 2021Publication date: June 24, 2021Inventors: Jae-Hoon KANG, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
-
Patent number: 10988449Abstract: The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).Type: GrantFiled: April 12, 2018Date of Patent: April 27, 2021Assignee: IL DONG Pharmaceutical Co., Ltd.Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang